Skip to main content
. 2022 Jul;11(7):2238–2248. doi: 10.21037/tcr-21-2633

Table 2. Results of univariate and multivariate analysis for recurrence-free survival.

Covariate Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Age (≥65 vs. <65 years) 0.97 0.59–1.58 0.89 NA NA NA
Male vs. female 1.53 0.94–2.51 0.09 1.81 0.81–4.02 0.15
Smoking status
   Light vs. never 1.19 0.57–2.45 0.65 0.39 0.13–1.18 0.09
   Heavy vs. never 2.61 1.36–5.00 0.004 1.33 0.52–3.42 0.56
ECOG PS
   1 vs. 0 1.60 0.95–2.69 0.08 1.33 0.74–2.42 0.35
   2 vs. 0 4.73 1.10–20.29 0.04 0.98 0.19–5.12 0.98
Tumor size (≥4 vs. <4 cm) 3.41 2.02–5.75 <0.001 1.94 1.03–3.67 0.04
Adenocarcinoma subtype (solid vs. non-solid) 1.91 0.91–4.03 0.09 1.36 0.38–4.82 0.64
Histologic grading
   Grade 1 1 1
   Grade 2 3.12 1.75–5.57 <0.001 1.35 0.65–2.83 0.42
   Grade 3 3.25 1.59–6.63 0.001 0.81 0.24–2.73 0.73
Lymphovascular invasion (yes vs. no) 2.86 1.73–4.75 <0.001 1.16 0.60-2.21 0.67
Visceral pleural invasion (yes vs. no) 3.48 2.11–5.72 <0.001 2.53 1.34–4.79 0.004
Tumor necrosis (yes vs. no) 4.58 2.75–7.62 <0.001 2.45 1.13–5.31 0.023
EGFR mutation (yes vs. no) 0.95 0.55–1.65 0.85 1.20 0.66–2.18 0.56
Bronchial resection margin (<2 vs. ≥2 cm) 2.34 1.41–3.90 0.001 1.96 1.10–3.51 0.023

HR, hazard ratio; CI, confidence interval; NA, not applicable; ECOG, Eastern Cooperative Oncology Group; PS, performance status.